Unapproved eye treatments get yanked by FDA
NEW YORK The Food and Drug Administration has told companies to stop selling eye solutions for use during surgery and for treating lesions without regulatory approval, citing dangerous side effects.
The drugs include ophthalmic balanced salt solutions for the eyes and topical drugs containing the papaya-based compound papain.
A number of companies have sold the unapproved eye drugs, including Baxter International and Hospira.
Bristol-Myers Squib ups off for ImClone buyout
NEW YORK Bristol-Myers Squibb announced Monday that it would increase its offer for ImClone after the biotech rejected a previous offer as too low.
Bristol had previously offered $60 a share for the company, but has increased its offer to $62 a share, or $4.7 billion. That’s still far below the $70 a share that ImClone chairman Carl Icahn has said an unnamed pharmaceutical company has offered.
ImClone and Bristol jointly market the cancer drug Erbitux (cetuximab), and Bristol owns 16.6 percent of ImClone’s stock.
Roche assures flu vaccines will be in stock for season
NUTLEY, N.J. Ample supplies of the flu drug Tamiflu will be available throughout the country during the flu season, manufacturer Roche said Tuesday.
The vaccine, known generically as oseltamivir phosphate, is approved for treating and preventing influenza in adults and children aged 1 and older.
The Centers for Disease Control and Prevention considers it an important second line of defense against the flu.
“We understand that pharmacists do their best to stock appropriate amounts of antiviral medications, such as Tamiflu, for use during the flu season,” Roche medical director Dominick Iacuzio said. “However, the incidence and severity of seasonal flu remains unpredictable from year to year, and some pharmacies may still be faced with greater-than-expected demand during the season.”